Brief: Clarity Pharmaceuticals Says FDA Gave Positive Feedback On Phase III Trial For Cu-Sar-Bispsma
14/10/2024 02:16
Oct 14 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX :
* U.S. FDA PROVIDED POSITIVE FEEDBACK ON PHASE III TRIAL FOR
CU-SAR-BISPSMA DIAGNOSTIC IN PROSTATE CANCER PATIENTS WITH BCR
Further company coverage: CU6.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial